Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
41.78
-0.36 (-0.85%)
At close: Nov 20, 2025, 4:00 PM EST
41.95
+0.17 (0.41%)
After-hours: Nov 20, 2025, 6:16 PM EST
Exelixis Revenue
Exelixis had revenue of $597.76M in the quarter ending September 30, 2025, with 10.79% growth. This brings the company's revenue in the last twelve months to $2.29B, up 9.93% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.29B
Revenue Growth
+9.93%
P/S Ratio
5.08
Revenue / Employee
$1,994,959
Employees
1,147
Market Cap
11.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EXEL News
- 10 days ago - Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 13 days ago - Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still - Seeking Alpha
- 14 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November - Business Wire
- 15 days ago - Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 4 weeks ago - Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Business Wire
- 4 weeks ago - Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results - Benzinga
- 4 weeks ago - Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet - Business Wire